<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To reduce the risk of therapy related complication during the treatment and keeps the long term event free survival, and to evaluate the results and risk factors of SCMC-lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ALL)-2005 protocol </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Designed the new protocol SCMC-ALL-2005 based on the previous protocol XH-99 for ALL </plain></SENT>
<SENT sid="2" pm="."><plain>Divided the patients into low, median and high risk groups depends on risk factors including day 33 and 55 minimal <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) level </plain></SENT>
<SENT sid="3" pm="."><plain>The higher risk group, the more intensive therapy was given </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the cases were registed on pediatric <z:hpo ids='HP_0002664'>oncology</z:hpo> network database (POND) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the abandonment patients were counted as event </plain></SENT>
<SENT sid="6" pm="."><plain>From May 1(st) 2005 to April 30(th) 2009, 351 children who were newly diagnosed as B lineage ALL were enrolled in this study </plain></SENT>
<SENT sid="7" pm="."><plain>The prognoses relating to risk grouping, age, mutation gene and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> level were analyzed </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Up to June 30, 2011, 273 patients were followed up with median time 49 months (range 26 to 74 months) </plain></SENT>
<SENT sid="9" pm="."><plain>Three hundred and forty-five patients (98.29%) achieved complete remission on day 35 induction </plain></SENT>
<SENT sid="10" pm="."><plain>12 cases were younger than 1 year old (3.42%), 285 cases between 1 and 9 years old (81.20%), 54 cases 10 to 18 years old (15.38%) </plain></SENT>
<SENT sid="11" pm="."><plain>Five year event-free survival (EFS) was 34%, 72% and 63%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>One hundred and fifty-six cases belonged to lowered risk (44.44%), 177 to middle risk (50.43%) and 18 to higher risk (5.13%) </plain></SENT>
<SENT sid="13" pm="."><plain>Five year EFS was 78%, 64% and 30%, respectively </plain></SENT>
<SENT sid="14" pm="."><plain>In this study, 18 patients were detected positive for BCR/ABL, 3 for MLL/AF4, 16 for PBX/E2A, and 36 for <z:chebi fb="18" ids="30182">TEL</z:chebi>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>The 5 year EFS were 11%, 66%, 75% and 74%, respectively </plain></SENT>
<SENT sid="16" pm="."><plain>A total of 300 cases were tested for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> levels on day 35 </plain></SENT>
<SENT sid="17" pm="."><plain>Of them, 241 cases were with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> â‰¤ 0.01% (negative), and 59 cases &gt; 0.01% (positive) </plain></SENT>
<SENT sid="18" pm="."><plain>The 5 year relapse free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) was 79% and 58%, respectively </plain></SENT>
<SENT sid="19" pm="."><plain>Total 6 patients died of complication (1.71%) </plain></SENT>
<SENT sid="20" pm="."><plain>18 patients were abundant treatment with no disease progress </plain></SENT>
<SENT sid="21" pm="."><plain>70 patients relapsed (19.94%), including 52 bone marrow, 8 central nerve system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>), 1 both in bone marrow and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>, 1 second <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (M(4)) and 8 testis </plain></SENT>
<SENT sid="22" pm="."><plain>Five year overall survival (OS) and EFS are 84% and 69% </plain></SENT>
<SENT sid="23" pm="."><plain>CONCLUSIONS: The risk of therapy related <z:hpo ids='HP_0011420'>death</z:hpo> is low with the protocol SCMC-ALL-2005 </plain></SENT>
<SENT sid="24" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> affects the prognosis </plain></SENT>
<SENT sid="25" pm="."><plain>The long term prognosis is poor for high risk group, with BCR/ABL and positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> </plain></SENT>
</text></document>